Peptide-mediated targeting of cytokines to tumor vasculature: The NGR-hTNF example

Angelo Corti, Flavio Curnis, Gilda Rossoni, Fabrizio Marcucci, Vanesa Gregorc

Research output: Contribution to journalArticle

Abstract

A growing body of evidence suggests that the efficacy of cytokines in cancer therapy can be increased by targeting strategies based on conjugation with ligands that recognize receptors expressed by tumor cells or elements of the tumor microenvironment, including the tumor vasculature. The targeting approach is generally conceived to permit administration of low, yet pharmacologically active, doses of drugs, thereby avoiding toxic reactions. However, it is becoming clear that, in the case of cytokines, this strategy has another inherent advantage, i.e. the possibility of administering extremely low doses that do not activate systemic counter-regulatory mechanisms, which may limit their potential therapeutic effects. This review is focused on the use of tumor vasculature-homing peptides as vehicles for targeted delivery of cytokines to tumor blood vessel. In particular, we provide an overview of peptide-cytokine conjugates made with peptides containing the NGR, RGD, isoDGR or RGR sequences and describe, in more details, the biological and pharmacological properties of NGR-hTNF, a peptide-tumor necrosis factor-α conjugate that is currently being tested in phase II and III clinical studies. The results of preclinical and clinical studies performed with these products suggest that peptide-mediated vascular-targeting is indeed a viable strategy for delivering bioactive amounts of cytokines to tumor endothelial cells without causing the activation of counter-regulatory mechanisms and toxic reactions.

Original languageEnglish
Pages (from-to)591-603
Number of pages13
JournalBioDrugs
Volume27
Issue number6
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Biotechnology

Fingerprint Dive into the research topics of 'Peptide-mediated targeting of cytokines to tumor vasculature: The NGR-hTNF example'. Together they form a unique fingerprint.

  • Cite this